Noninvasive Continuous Glucose Monitoring With a Novel Wearable Dial Resonating Sensor: A Clinical Proof-of-Concept Study
Authors' conclusion
This proof-of-concept study shows that a novel noninvasive continuous glucose monitor was capable of detecting glucose levels. Furthermore, the ARD results are comparable to first models of commercially available minimally invasive products without the need to insert a needle. The prototype has been further developed and is being tested in subsequent studies.
Study context
- Population
- Male participants with T1D, age range 19–56 years, at varying levels of glycemiamale, T1D
- Participants
- 29 participants
- Comparison
- Noninvasive wearable dial resonating sensor vs laboratory venous blood glucose (Super GL Glucose Analyzer)
- Prototype investigational devicen = 29
- Outcome
- Co-primary: median and mean absolute relative difference (ARD) across all data points
Methodological detailssingle-arm, open-label, experimental, three stages
- Single-arm
- Open-label
- Experimental
- Three stages
Main finding
As reported in the abstract
- Stage 1 (initial proof-of-principle): median absolute relative difference (ARD)
- 30%
- Stage 1: mean ARD
- 46%
- Stage 2 (improved device design): median ARD
- 22%
- Stage 2: mean ARD
- 28%
- Stage 3 (two consecutive days, no recalibration): median ARD
- 35%
- Stage 3: mean ARD
- 44%
Original publication
Noninvasive Continuous Glucose Monitoring With a Novel Wearable Dial Resonating Sensor: A Clinical Proof-of-Concept Study. J Diabetes Sci Technol. Published 27 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →